MAKING SCIENCE

Changes in estimates to reflect US expansion


- **Highlights from c/call.** CEO Mr. Martínez Aguilar held yesterday a c/call to review FY22 (released on April 18th) and 1Q23 (released on May 17th) results, as well as to update on the company's outlook. We highlight the following:
 - a) Despite macro uncertainties, market trends remain positive across all geographies and services (marginally stronger in data & technology compared with digital advertising, which has a bigger cyclical component). The strong organic growth is split (50% from new clients & from 50% existing ones).
 - b) The jump in staff costs (+c.40% in Q1, vs. +c.30% in gross profit) came from wage inflation and, more importantly, from a step-up of the commercial team in Europe, which should accelerate sales in the coming quarters.
 - c) As for the expansion into the US, the rationale is two-fold: 1) to enter the world's largest market (>50% of digital advertising, vs. <1% of Making Science revenues); and 2) to supply the recently hired senior ex-Google team with Making Science's: a) strong know-how in the US' most important niches (i.e. video & search advertising); b) long-standing relationship with Google in EMEA (it is one of the few GMP resellers); c) cost competitive hubs; and 4) extensive client portfolio. Management highlighted the potential of Local Planet (one of the largest media agency networks, 11% owned by Making Science) as a good client feed & prescriber in their US expansion.</p>
 - d) As for Ventis, after its first ever break-even quarter in Q1, MKS maintained its target of being break-even in FY23 and profit-making in FY24. In addition, management admitted to being open to sell Ventis at the right price.
- Cutting 2023 estimates but fine-tuning 2024-25. We are reflecting: 1) faster gross profit growth at the core business, at the expense of greater staff costs; 2) a c.€2m negative contribution from the US in 2023 (close to breakeven in 2024 and positive contribution in 2025); and 3) a slight improvement in Ventis (marginally loss making in 2023 & profit making in 2024). As a result, we are raising our 2023-25 gross profit estimates by 5-13% p.a., but cutting EBITDA in 2023 by c.15% to €10.5m, trimming 2024 by 3% to >€14m and slightly raising 2025 by c.5% to c.€18m. We expect the significant investment efforts to be dilutive in the short term, but they should ultimately reinforce the company's product and geographical mix and bring significant growth potential in 1-2Y.

Financial Ratios	FY20	FY21	FY22	FY23E	FY24E	FY25E					
EBITDA (€m)	3.7	5.7	9.2	10.5	14.3	17.7					
Net profit (€m)	1.5	(3.5)	(5.0)	(2.1)	1.3	4.7					
EPS (€)	0.22	(0.45)	(0.59)	(0.25)	0.15	0.56					
Adj. EPS (*) (€)	0.33	0.37	0.35	0.42	0.78	1.11					
P/E (x)		n.a	n.a	n.a.	69.7	19.2					
P/E Adj. (x)		68.4	44.9	25.3	13.8	9.6					
EV/EBITDA (x)		38.7	17.3	11.2	7.8	5.7					
Debt/EBITDA (x)	0.7	4.1	2.7	2.6	1.4	0.6					
P/BV (x)		18.7	9.7	7.7	7.0	5.1					
ROE (%)		(33.2)	(36.2)	n.a.	10.0	26.6					
DPS (€)	0.0	0.0	0.0	0.00	0.00	0.00					
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	0.0					
(*) Historical multiples based on average share price of the year											

SPONSORED RESEARCH

Share Price (*)	€ 10.70
*Share price at the	e close of 29 May 2023

MAKS.MC/	
Market Cap	€ 93 m
Enterprise Value	€ 117 m
Free Float	€ 21 m
Nº Shares	8 m
Average Daily Volume	€ 300 k



Analyst

Fernando Abril-Martorell +34 915508719 fabril@alantraequities.com

Making Science

ALANTRA Equities

KEY DATA															
P&L account (€ m)	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E	Cash flow (€ m)	FY19	FY20	FY21	FY22	FY23E	FY24E	FY
Revenue	34.6	57.7	110.4	210.1	248.4	293.5	337.7	Net profit	0.7	1.5	(3.5)	(5.0)	(2.1)	1.3	
COGS	(26.1)	(42.9)	(80.4)	(155.2)	(182.1)	(215.2)	(247.6)	Depreciation	0.4	0.9	3.8	7.6	7.9	7.8	
Gross margin	8.4	14.8	30.0	55.0	66.3	78.4	90.1	Minorities		-	0.3	0.4	0.2	0.2	
Opex	(7.1)	(11.3)	(27.7)	(47.4)	(56.9)	(64.6)	(72.6)	Non-cash adjustments	0.1	0.7	(0.2)	(2.5)	0.5	0.7	
EBITDA	1.4	3.5	2.4	7.5	9.4	13.8	17.5	Total cash-flow (CF)	1.2	3.1	0.5	0.5	6.5	10.0	
One-offs	1.0	0.2	3.4	1.7	1.1	0.6	0.3	Capex	(0.8)	(1.2)	(3.1)	(4.7)	(4.3)	(4.3)	
Adj. EBITDA	2.4	3.7	5.7	9.2	10.5	14.3	17.7	Working capital investment	0.7	0.5	5.8	5.7	1.0	1.0	
D&A	(0.4)	(0.9)	(3.8)	(7.6)	(7.9)	(7.8)	(7.5)	Operating FCF	1.1	2.4	3.1	1.6	3.2	6.7	
Provisions & Other	(0.0)	-	(0.0)	(0.0)	-	-	-	Financial investments	-	-	-	-	-	-	
EBIT	0.9	2.6	(1.5)	(0.1)	1.6	5.9	10.0	Disposals (acquisitions)	(0.7)	(5.0)	(34.3)	(14.7)	(5.5)	-	
Net financials	(0.1)	(0.4)	(0.8)	(1.9)	(2.5)	(2.4)	(2.1)	Other				-	-	-	
Equity method & other	0.0	(0.1)	(0.3)	(1.1)	-		-	Dividends to minorities				-	-		
BT	0.8	2.1	(2.5)	(3.0)	(1.0)	3.5	7.9	Rights issues		1.2	10.6	11.8	-		
ncome tax expense	(0.1)	(0.5)	(0.7)	(1.5)	(0.9)	(2.0)	(2.9)	Free-cash-flow (FCF)	0.4	(1.5)	(20.5)	(1.4)	(2.3)	6.7	
Minorities	-		(0.3)	(0.4)	(0.2)	(0.2)	(0.3)	Dividends paid				-	-		
Net profit, reported	0.7	1.5	(3.5)	(5.0)	(2.1)	1.3	4.7	Share buybacks					-		
Adjustments	1.1	0.9	6.4	8.0	5.7	5.2	4.7	FCF after buy backs	0.4	(1.5)	(20.5)	(1.4)	(2.3)	6.7	
Net profit adjusted	1.8	2.4	2.9	3.0	3.6	6.5	9.4			. ,	. ,	. ,	. ,		
								Balance sheet (€ m)	FY19	FY20	FY21	FY22	FY23E	FY24E	F
№ of shares (m)	6.7	7.1	7.8	8.4	8.4	8.4	8.4	Shareholders equity	0	3	11	14	12	13	_
№ of shares adjusted (m)	6.4	6.8	7.6	8.2	8.2	8.2	8.2	Minorities		-	1	1	1	1	
Treasury stock (m)	0.3	0.3	0.2	0.2	0.2	0.2	0.2	Provisions & others	2	5	5	8	8	9	
	0.0	0.0	0.2	0.2	0.2	0.2	0.2	Net debt (cash)	- 1	3	23	25	27	20	
YoY Growth	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E	Capital invested	4	10	40	47	48	44	
Sales	83%	67%	92%	90%	18%	18%	15%		·						
BITDA	(9%)	153%	(32%)	220%	25%	46%	27%	Other intangible	5	11	40	49	51	47	
Adj. EBITDA	49%	54%	55%	61%	14%	36%	24%	PP&E	0	0	1	2	2	2	
ЕВП	(142%)	193%	(158%)	(96%)	n.m.	281%	68%	Financial assets	0	0	1	0	0	0	
Net profit	(128%)	132%	(10070) n.m.	43%	(58%)	(162%)	263%	Equity method	0	0	0	1	1	1	
not pront	(12070)	10270		4070	(0070)	(10270)	20070	Working capital	(2)	(1)	(2)	(5)	(6)	(7)	
Sales by division	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E		(2) 4	10	(2) 40	(3) 47	(0) 48	(7) 44	
Core Business	100%	100%	94%	92%	96%	96%	97%		(5.5%)				(2.5%)	(2.4%)	(2
								Working capital/sales	(0.076)	(2.1%)	(1.4%)	(2.4%)	(2.376)	(2.470)	(2
E-commerce	0%	0%	6%	5%	4%	4%	3%	Financial vation	5740	5730	57.24	57,33	EVO2E	EVOAE	_
	5/40	5/00	D/04	5/00	5/005	5/045	DIALE	Financial ratios	FY19	FY20	FY21	FY22	FY23E	FY24E	F
EBITDA by division	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E	Net debt/EBITDA	0.9X	0.8X	9.9X	3.3X	2.9X	1.5X	
Core Business	100%	100%	125%	126%	103%	98%	97%	Net debt/Adj. EBITDA	0.5X	0.7X	4.1X	2.7X	2.6X	1.4X	
E-commerce	0%	0%	(25%)	(26%)	(3%)	2%	3%	Gearing	283%	95%	222%	179%	231%	156%	
								Interest cover	8.0X	5.7X	(1.9X)	(0.0X)	0.6X	2.4X	
Per share data	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E								
EPS	0.10	0.22	(0.45)	(0.59)	(0.25)	0.15	0.56	Margins & ratios	FY19	FY20	FY21	FY22	FY23E	FY24E	F
EPS adjusted	0.26	0.34	0.37	0.35	0.42	0.78	1.11	EBITDA margin	4%	6%	2%	4%	4%	5%	
CFPS	0.18	0.44	0.06	0.06	0.77	1.19	1.58	Effective tax rate	(14%)	(26%)	26%	50%	93%	(56%)	(:
FCFPS	0.16	0.34	0.40	0.19	0.38	0.80	1.19	Pay-out	0%	0%	0%	0%	0%	0%	
BVPS	0.07	0.41	1.35	1.63	1.38	1.54	2.10	ROCE (EBIT/CE)	23%	25%	(4%)	(0%)	3%	14%	
DPS		-	-	-	-		-	ROE	151%	54%	n.a.	n.a.	n.a.	10%	

Alantra Equities: This report (the "Report") has been prepared by Alantra Equities Sociedad de Valores, S.A. ("Alantra Equities"), a company pertaining to the Alantra Group that provides investment banking, asset management, equities brokerage, capital markets and financial advisory services. The date and hour of preparation of this investment recommendation refers to the date and hour of preparation and disclosure indicated on the first page of the Report.

Alantra Equities Sociedad de Valores, S.A. is a Spanish investment firm located in Madrid, calle José Ortega y Gasset 29, registered at the Comisión Nacional del Mercado de Valores (CNMV) with number 245.

Analyst certification: Each research analyst primarily responsible for the content of this research Report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this Report: (i) all the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, and (ii) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that research analyst in this research Report.

Important disclosures:

Alantra Equities receives remuneration from the issuer that this Report refers to in consideration of the research services that Alantra Equities provides to it. Therefore, this Report is considered sponsored research or marketing material for the purposes of the provisions of the Markets in Financial Instruments Directive.

Within the last 12 months, Alantra Equities is participating as co-global coordinator in connection with the capital increase of Making Science Group S.A.

This Report is solely for the information of clients of Alantra Equities and for distribution only under such circumstances as may be permitted by applicable law. Alantra Equities specifically prohibits the redistribution of this material in whole or in part without the prior written permission of Alantra Equities and therefore Alantra Equities accepts no liability whatsoever for the actions or third parties in this respect.

The opinions contained in this report and in other media used by Alantra Equities (such as the internet), reflect the opinion of the respective Analyst on the date of publication of such material and, therefore, may be subject to change at any time and without notice.

Nothing in this Report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. This Report is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor it is intended to be a complete statement or summary of the securities or markets referred to in this Report. Alantra Equities does not undertake that investors will obtain profits nor accept any liability for any investment losses arising from any use of this Report or its contents. Investments involve risks and investors should exercise prudence in making their investment decisions. This Report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this Report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas of the Alantra Group as a result of using different assumptions and criteria. Research will be initiated, updated and coverage ceased solely at the discretion of Alantra Equities. The analysis contained there in is based on numerous assumptions. Different assumptions could result in materially different results. Alantra Equities is under no obligation to keep current the information contained in this Report.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this Report.

Any prices stated in this Report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices.

Neither Alantra Equities nor any of the companies pertaining to the Alantra Group nor any of their shareholders, directors, employees or agents accept any liability for any loss or damage arising out of the use of all or any part of this Report.

Except as otherwise specified herein, this material is communicated by Alantra Equities to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to retail clients.

Important disclosures on conflicts of interest:

The analysts responsible for the preparation of this Report may interact with trading desk personnel, sales personnel and investment managers. Alantra Equities belongs to the Alantra Group, a group that is engaged in financial advisory services, asset management as well as securities trading and brokerage, and capital markets. Alantra Equities, any other company pertaining to the Alantra Group, and any of their shareholders, directors, employees may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments directly or indirectly the subject of this publication. The Alantra Group relies on information barriers to control the flow of information contained in one or more areas within the Alantra Group, into other areas, units, groups or affiliates of the Alantra Group. The Alantra Group may do and seek to do business with companies covered in its research reports. As a result, investors should be aware that the Alantra Group may have a conflict of interest.

For the purposes of mitigating any conflict of interests, the Alantra Group has established, implemented and maintains an effective conflicts of interest policy appropriate to its size and organisation and to the nature, scale and complexity of its business. The policy, periodically revised, can be consulted at the Alantra Equities website through the following link: Conflicts of Interest. Investors should consider this Report as only a single factor in making their investment decisions. In addition, Alantra Group's website (www.alantra.com) provides information on closed and public corporate transactions, not subject to confidentiality, in which the Alantra Group, through its subsidiaries in the investment banking area, has acted as financial advisor, from time to time.

The disclosures contained in research Report produced by Alantra Equities shall be governed by and construed in accordance with Spanish law.

The receipt of this Report implies full acceptance by its recipients of the contents of this disclaimer.